Immune cells take on rare muscle disease in early trial
NCT ID NCT07243366
First seen Nov 21, 2025 · Last updated May 13, 2026 · Updated 17 times
Summary
This early-stage trial tests a new treatment using donor immune cells (CAR-NK cells) that are designed to target and calm the overactive immune system in people with severe myasthenia gravis. The study will enroll 15 adults aged 18-65 whose condition has not responded to standard therapies. The main goal is to check safety, while also tracking changes in daily living and muscle strength.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.